Trial Profile
A phase II study of MGI-114 [irofulven] in patients with recurrent or persistent epithelial ovarian cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2011
Price :
$35
*
At a glance
- Drugs Irofulven (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 30 May 2007 New trial record.